117854-05-4

Basic information

• Product Name: L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 4-(1,1-dimethylethyl) 1-(phenylmethyl) ester
• CAS NO: 117854-05-4
• Molecular Formula: C30H31NO6
• Molecular Weight: 501.579
• Mol File: 117854-05-4.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 4-(1,1-dimethylethyl) 1-(phenylmethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 4-(1,1-dimethylethyl) 1-(phenylmethyl) ester(117854-05-4)
• EPA Substance Registry System: L-Aspartic acid, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, 4-(1,1-dimethylethyl) 1-(phenylmethyl) ester(117854-05-4)

Safety Data

• Hazardous Substances Data: 117854-05-4(Hazardous Substances Data)

Upstream product

• 71989-14-5 Fmoc-(tBu)Asp-OH 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 100-51-6 benzyl alcohol 

Downstream Products

• 647847-95-8 (2S)-benzyl 2-(N-(9-fluorenylmethoxycarbonyl)amino)-4-hydroxybutanoate 
• 1415221-85-0 N--Fmoc--(2S)-2--amino--4--oxo--4--((8--phenyloctyl)amino)butanoic acid 
• 1415221-95-2 benzyl N--Fmoc--(2S)--2--amino--4--oxo--4--((8--phenyloctyl)amino)butanoate 
• 157886-21-0 Fmoc-Glu(Ot-Bu)-Asp(Ot-Bu)-OBn 
• 936749-33-6 1-benzyl 4-tert-butyl N-(1-adamantylcarbonyl)-L-aspartate 
• 936823-86-8 1-benzyl 4-tert-butyl N-((bicyclo[2.2.1]heptan-2-yl)acetyl)-L-aspartate 
• 936749-32-5 1-benzyl 4-tert-butyl N-(cyclohexylcarbonyl)-L-aspartate 
• 936749-31-4 1-benzyl 4-tert-butyl N-(cyclopentylcarbonyl)-L-aspartate 
• 936749-43-8 4-tert-butyl N^α-(1-adamantylcarbonyl)-N-{4-[4-(3-chlorophenyl)piperazin-1-yl]butyl}-L-aspartamide 
• 936823-89-1 4-tert-butyl N^α-((bicyclo[2.2.1]heptan-2-yl)acetyl)-N-{4-[4-(3-chlorophenyl)piperazin-1-yl]butyl}-L-aspartamide 
• 936749-42-7 4-tert-butyl N^α-(cyclohexylcarbonyl)-N-{4-[4-(3-chlorophenyl)piperazin-1-yl]butyl}-L-aspartamide 
• 936749-41-6 4-tert-butyl N^α-(cyclopentylcarbonyl)-N-{4-[4-(3-chlorophenyl)piperazin-1-yl]butyl}-L-aspartamide 
• 936749-40-5 4-tert-butyl N^α-(1-adamantylcarbonyl)-N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-L-aspartamide 
• 936823-88-0 4-tert-butyl N^α-((bicyclo[2.2.1]heptan-2-yl)acetyl)-N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-L-aspartamide 

Relevant articles and documents

THE PREPARATION OF A PARTIALLY PROTECTED HEPTASACCHARIDE-ASPARAGINE INTERMEDIATE FOR GLYCOPEPTIDE SYNTHESIS

The heptasaccharide O-α-D-mannopyranosyl-(1->6)-O-3)>-O-α-D-mannopyranosyl-(1->6)-O-3)>-O-β-D-mannopyranosyl-(1->4)-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1->4)-2-acetamido-2-deoxy-D-glucopyranose, isol

Total Synthesis of Malacidin A by β-Hydroxyaspartic Acid Ligation-Mediated Cyclization and Absolute Structure Establishment

The development of novel antibiotics is critical to combating the growing emergence of drug-resistant pathogens. Malacidin A is a new member of the calcium-dependent antibiotic (CDAs) family with activity against antibiotic-resistant pathogens. Its mode of action is distinct from classical CDAs. However, the absolute structure of malacidin A has not been established. Herein, the total syntheses of malacidin A and its analogues are reported by a combination of Fmoc-based solid-phase peptide synthesis (SPPS) and β-hydroxyaspartic acid ligation-mediated peptide cyclization. The total synthesis enabled us to establish the absolute configuration of malacidin A, which is in agreement with those for natural malacidin A confirmed by advanced Marfey's analysis in our study.

MULTICYCLIC PEPTIDES AND METHODS FOR THEIR PREPARATION

The invention relates to methods for preparing a compound comprising a peptide attached to a molecular scaffold whereby multiple peptide loops are formed, to compounds that can be obtained with such methods and uses thereof.

Parallel synthesis of an oligomeric imidazole-4, 5-dicarboxamide library

A library of oligomeric compounds was synthesized based on the imidazole-4, 5-dicarboxylic acid scaffold along with amino acid esters and chiral diamines derived from amino acids. The final compounds incorporate nonpolar amino acids (Leu, Phe, Trp), polar amino acids (Ser, Asp, Arg), and neutral amino acids (Gly, Ala), and were designed to be useful in screening for inhibitors of protein-protein interactions. Many of the protected and deprotected oligomers show evidence of conformational isomers persistent at room temperature in aqueous solution. A total of 317 final oligomers, out of 441 targeted compounds, were obtained in high analytical purity and of sufficient quantity to submit them for high-throughput screening as part of the NIH Roadmap.